486 related articles for article (PubMed ID: 23143980)
1. Tumor dormancy: long-term survival in a hostile environment.
Quesnel B
Adv Exp Med Biol; 2013; 734():181-200. PubMed ID: 23143980
[TBL] [Abstract][Full Text] [Related]
2. Tumor dormancy and cancer stem cells: two sides of the same coin?
Kleffel S; Schatton T
Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
[TBL] [Abstract][Full Text] [Related]
3. Tumor dormancy and immunoescape.
Quesnel B
APMIS; 2008; 116(7-8):685-94. PubMed ID: 18834412
[TBL] [Abstract][Full Text] [Related]
4. Dormant tumor cells as a therapeutic target?
Quesnel B
Cancer Lett; 2008 Aug; 267(1):10-7. PubMed ID: 18384938
[TBL] [Abstract][Full Text] [Related]
5. The acidic microenvironment as a possible niche of dormant tumor cells.
Peppicelli S; Andreucci E; Ruzzolini J; Laurenzana A; Margheri F; Fibbi G; Del Rosso M; Bianchini F; Calorini L
Cell Mol Life Sci; 2017 Aug; 74(15):2761-2771. PubMed ID: 28331999
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease in cancer therapy--Small things make all the difference.
Blatter S; Rottenberg S
Drug Resist Updat; 2015; 21-22():1-10. PubMed ID: 26307504
[TBL] [Abstract][Full Text] [Related]
7. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
Indraccolo S
Adv Exp Med Biol; 2013; 734():37-52. PubMed ID: 23143974
[TBL] [Abstract][Full Text] [Related]
8. Cellular dormancy in minimal residual disease following targeted therapy.
Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
[TBL] [Abstract][Full Text] [Related]
9. Targeting Cancer Cell Dormancy.
Recasens A; Munoz L
Trends Pharmacol Sci; 2019 Feb; 40(2):128-141. PubMed ID: 30612715
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia.
Ebinger S; Özdemir EZ; Ziegenhain C; Tiedt S; Castro Alves C; Grunert M; Dworzak M; Lutz C; Turati VA; Enver T; Horny HP; Sotlar K; Parekh S; Spiekermann K; Hiddemann W; Schepers A; Polzer B; Kirsch S; Hoffmann M; Knapp B; Hasenauer J; Pfeifer H; Panzer-Grümayer R; Enard W; Gires O; Jeremias I
Cancer Cell; 2016 Dec; 30(6):849-862. PubMed ID: 27916615
[TBL] [Abstract][Full Text] [Related]
11. The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer.
Ferguson LP; Diaz E; Reya T
Trends Cancer; 2021 Jul; 7(7):624-634. PubMed ID: 33509688
[TBL] [Abstract][Full Text] [Related]
12. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.
Tamura H; Ishibashi M; Yamashita T; Tanosaki S; Okuyama N; Kondo A; Hyodo H; Shinya E; Takahashi H; Dong H; Tamada K; Chen L; Dan K; Ogata K
Leukemia; 2013 Feb; 27(2):464-72. PubMed ID: 22828443
[TBL] [Abstract][Full Text] [Related]
13. Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting.
Talukdar S; Bhoopathi P; Emdad L; Das S; Sarkar D; Fisher PB
Adv Cancer Res; 2019; 141():43-84. PubMed ID: 30691685
[TBL] [Abstract][Full Text] [Related]
14. Multifaceted kinetics of immuno-evasion from tumor dormancy.
d'Onofrio A
Adv Exp Med Biol; 2013; 734():111-43. PubMed ID: 23143978
[TBL] [Abstract][Full Text] [Related]
15. [Tumor dormancy and identification of therapeutic targets].
Li CF; Cao S; Meng SD
Ai Zheng; 2009 May; 28(5):555-8. PubMed ID: 19624889
[TBL] [Abstract][Full Text] [Related]
16. PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.
Crane CA; Panner A; Murray JC; Wilson SP; Xu H; Chen L; Simko JP; Waldman FM; Pieper RO; Parsa AT
Oncogene; 2009 Jan; 28(2):306-12. PubMed ID: 18850006
[TBL] [Abstract][Full Text] [Related]
17. Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma.
Wu X; Peng M; Huang B; Zhang H; Wang H; Huang B; Xue Z; Zhang L; Da Y; Yang D; Yao Z; Zhang R
Cancer Lett; 2013 Oct; 340(1):124-33. PubMed ID: 23920127
[TBL] [Abstract][Full Text] [Related]
18. Genes and regulatory pathways involved in persistence of dormant micro-tumors.
Almog N
Adv Exp Med Biol; 2013; 734():3-17. PubMed ID: 23143972
[TBL] [Abstract][Full Text] [Related]
19. Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications.
Rossari F; Zucchinetti C; Buda G; Orciuolo E
Cell Oncol (Dordr); 2020 Apr; 43(2):155-176. PubMed ID: 31392521
[TBL] [Abstract][Full Text] [Related]
20. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
